The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Current understanding and management of CAR T cell-associated toxicities
Open accessAbstract
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of several haematological malignancies and is being investigated in patients with various solid tumours. Characteristic CAR T cell-associated toxicities such as cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are now well-recognized, and improved supportive care and management with immunosuppressive agents has made CAR T cell therapy safer and more feasible than it was when the first regulatory approvals of such treatments were granted in 2017. The increasing clinical experience with these therapies has also improved recognition of previously less well-defined toxicities, including movement disorders, immune effector cell-associated haematotoxicity (ICAHT) and immune effector cell-associated haemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), as well as the substantial risk of infection in patients with persistent CAR T cell-induced B cell aplasia and hypogammaglobulinaemia. A more diverse selection of immunosuppressive and supportive-care pharmacotherapies is now being utilized for toxicity management, yet no universal algorithm for their application exists. As CAR T cell products targeting new antigens are developed, additional toxicities involving damage to non-malignant tissues expressing the target antigen are a potential hurdle. Continued prospective evaluation of toxicity management strategies and the design of less-toxic CAR T cell products are both crucial for ongoing success in this field. In this Review, we discuss the evolving understanding and clinical management of CAR T cell-associated toxicities. Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of various haematological malignancies but is associated with characteristic toxicities as well as less well-defined adverse effects, many of which can be severe and potentially fatal. The increasing clinical experience with CAR T cell products has resulted in better recognition and management of these toxicities using a range of pharmacotherapies, although this is an area of continued evolution and refinement. In this Review, Brudno and Kochenderfer discuss the current understanding and clinical management of CAR T cell-associated toxicities. As clinicians have gained more experience with chimeric antigen receptor (CAR) T cell therapy, the management of cytokine-release syndrome (CRS) has improved, especially with use of the IL-6 receptor antagonist tocilizumab. In addition, monitoring and treatment of immune effector cell-associated neurotoxicity syndrome (ICANS) has improved with refinements to supportive care and glucocorticoid use. Movement disorders are an infrequent complication of B cell maturation antigen (BCMA)-directed CAR T cells, are difficult to manage and can be life-threatening. Prolonged cytopenias, secondary haemophagocytic lymphohistiocytosis and infectious complications are increasingly well recognized, and consensus guidelines have been developed for their management. New T cell malignancies have been reported after CAR T cell therapy but are exceedingly rare. Patients should be monitored for second malignancies indefinitely following CAR T cell therapy. Future directions in this field include the development of less-toxic CAR T cell products. As clinicians have gained more experience with chimeric antigen receptor (CAR) T cell therapy, the management of cytokine-release syndrome (CRS) has improved, especially with use of the IL-6 receptor antagonist tocilizumab. In addition, monitoring and treatment of immune effector cell-associated neurotoxicity syndrome (ICANS) has improved with refinements to supportive care and glucocorticoid use. Movement disorders are an infrequent complication of B cell maturation antigen (BCMA)-directed CAR T cells, are difficult to manage and can be life-threatening. Prolonged cytopenias, secondary haemophagocytic lymphohistiocytosis and infectious complications are increasingly well recognized, and consensus guidelines have been developed for their management. New T cell malignancies have been reported after CAR T cell therapy but are exceedingly rare. Patients should be monitored for second malignancies indefinitely following CAR T cell therapy. Future directions in this field include the development of less-toxic CAR T cell products.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 4×
“Retrospective analyses of data from clinical trials indicate that the use of tocilizumab to treat established CRS has no effect on blood CAR T cell levels 8,40 .”
InfluentialTisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112 · cited 1×
“75) was used to grade neurological toxicity in the first trials leading to FDA approval of all now commercially available CAR T cell products 1,2,4,5,8–10 except cilta-cel, for which neurological toxicity was graded using the ASTCT ICANS scale in the phase II portion of the CARTITUDE-1 trial 11 .”
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Self-citationChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 5×
“ASTCT, American Society of Transplantation and Cellular Therapy; axi-cel, axicabtagene ciloleucel; BCMA, B cell maturation antigen; brexu-cel, brexucabtagene autoleucel; CAR, chimeric antigen receptor; cilta-cel, ciltacabtagene autoleucel; CRS, cytokine-release syndrome; CTCAE, Common Terminology Criteria for Adverse…”
InfluentialLong-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560 · cited 7×
“In the initial pivotal trials of the currently approved CAR T cell therapies, use of anakinra for the management of active ICANS was limited to a few patients 10,11 , although this agent is now commonly used as the standard-of-care treatment for glucocorticoid-refractory ICANS 58,62 .”
InfluentialEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438 · cited 1×
“The CARTOX group initially proposed diagnostic criteria, a grading scale and management guidelines for secondary HLH related to CAR T cell therapy, including a stepwise approach using tocilizumab, escalating doses of glucocorticoids and etoposide 118 .”
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31366-0 · Cited by 2,430 · cited 8×
“1), and less commonly before CRS 1,6,40,70 .”
InfluentialKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914347 · Cited by 1,862 · cited 9×
“Patients with grade ≥3 neurological events have higher levels of inflammatory cytokines and immunological proteins (such as granzymes and CRP) in the CSF than those with grade 0−2 events 8,70 , suggesting that these proteins are involved in the pathogenesis.”
InfluentialBerdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756 · cited 9×
“In the initial pivotal trials of the currently approved CAR T cell therapies, use of anakinra for the management of active ICANS was limited to a few patients 10,11 , although this agent is now commonly used as the standard-of-care treatment for glucocorticoid-refractory ICANS 58,62 .”
InfluentialPorter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M.-A., Kersten, M.-J., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116133 · Cited by 1,607
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Self-citationKochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Self-citationNorelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406 · cited 3×
“mouse models of CRS have demonstrated no effect of tocilizumab on the anti-leukaemia activity of CAR T cell 39 .”
Gust, J., Hay, K. A., Hanafi, L.-A., Li, D., Myerson, D., Gonzalez-Cuyar, L. F., Yeung, C., Liles, W. C., Wurfel, M., Lopez, J. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0698 · Cited by 1,400 · cited 4×
“Not surprisingly, high-grade neurological toxicities occur more often in patients who have high-grade CRS 1,35,70 .”
InfluentialToxicities of chimeric antigen receptor T cells: recognition and management
Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283
Self-citationCAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272
Hay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D., Harju-Baker, S., et al. (2017) · Blood · doi:10.1182/blood-2017-06-793141 · Cited by 1,156 · cited 2×
“101), and more severe CRS 25,96,98,101,102 and/or ICANS 98 .”
Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0040 · Cited by 1,102
Santomasso, B. D., Park, J. H., Salloum, D., Riviere, I., Flynn, J., Mead, E., Halton, E., Wang, X., Senechal, B., Purdon, T., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1319 · Cited by 942
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Brudno, J. N., & Kochenderfer, J. N. (2019) · Blood Reviews · doi:10.1016/j.blre.2018.11.002 · Cited by 899
Self-citationLe, R. Q., Li, L., Yuan, W., Shord, S. S., Nie, L., Habtemariam, B. A., Przepiorka, D., Farrell, A. T., & Pazdur, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0028 · Cited by 873
Shah, B. D., Ghobadi, A., Oluwole, O. O., Logan, A. C., Boissel, N., Cassaday, R. D., Leguay, T., Bishop, M. R., Topp, M. S., Tzachanis, D., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01222-8 · Cited by 820
Nastoupil, L. J., Jain, M. D., Feng, L., Spiegel, J. Y., Ghobadi, A., Lin, Y., Dahiya, S., Lunning, M., Lekakis, L., Reagan, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02104 · Cited by 801
Brudno, J. N., Maric, I., Hartman, S. D., Rose, J. J., Wang, M., Lam, N., Stetler-Stevenson, M., Salem, D., Yuan, C., Pavletic, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8084 · Cited by 781
Self-citationJacobson, C. A., Chavez, J. C., Sehgal, A. R., William, B. M., Munoz, J., Salles, G., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00591-x · Cited by 666
Martin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00842 · Cited by 663 · cited 3×
“Second myeloid malignancies are well-known to occur after CAR T cell therapy but are usually attributed to prior chemotherapy regimens and/or autologous HSCT, rather than to the CAR T cell product itself 5,6,9,11,81,88 .”
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
Weber, E. W., Parker, K. R., Sotillo, E., Lynn, R. C., Anbunathan, H., Lattin, J., Good, Z., Belk, J. A., Daniel, B., Klysz, D., et al. (2021) · Science · doi:10.1126/science.aba1786 · Cited by 607
Brudno, J. N., Somerville, R. P. T., Shi, V., Rose, J. J., Halverson, D. C., Fowler, D. H., Gea-Banacloche, J. C., Pavletic, S. Z., Hickstein, D. D., Lu, T. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.5929 · Cited by 605
Self-citationTisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Fowler, N. H., Dickinson, M., Dreyling, M., Martinez-Lopez, J., Kolstad, A., Butler, J., Ghosh, M., Popplewell, L., Chavez, J. C., Bachy, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01622-0 · Cited by 555
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Mestermann, K., Giavridis, T., Weber, J., Rydzek, J., Frenz, S., Nerreter, T., Mades, A., Sadelain, M., Einsele, H., & Hudecek, M. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5907 · Cited by 531
Locke, F. L., Rossi, J. M., Neelapu, S. S., Jacobson, C. A., Miklos, D. B., Ghobadi, A., Oluwole, O. O., Reagan, P. M., Lekakis, L. J., Lin, Y., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002394 · Cited by 489
Rejeski, K., Perez, A., Sesques, P., Hoster, E., Berger, C., Jentzsch, L., Mougiakakos, D., Frölich, L., Ackermann, J., Bücklein, V., et al. (2021) · Blood · doi:10.1182/blood.2020010543 · Cited by 475
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
Westin, J. R., Oluwole, O. O., Kersten, M. J., Miklos, D. B., Perales, M.-A., Ghobadi, A., Rapoport, A. P., Sureda, A., Jacobson, C. A., Farooq, U., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301665 · Cited by 455
Pasquini, M. C., Hu, Z.-H., Curran, K., Laetsch, T., Locke, F., Rouce, R., Pulsipher, M. A., Phillips, C. L., Keating, A., Frigault, M. J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003092 · Cited by 450
Hayden, P. J., Roddie, C., Bader, P., Basak, G. W., Bonig, H., Bonini, C., Chabannon, C., Ciceri, F., Corbacioglu, S., Ellard, R., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.003 · Cited by 442
Thompson, J. A., Schneider, B. J., Brahmer, J., Achufusi, A., Armand, P., Berkenstock, M. K., Bhatia, S., Budde, L. E., Chokshi, S., Davies, M., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0020 · Cited by 426
Shah, N. N., Highfill, S. L., Shalabi, H., Yates, B., Jin, J., Wolters, P. L., Ombrello, A., Steinberg, S. M., Martin, S., Delbrook, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03279 · Cited by 421
Santomasso, B. D., Nastoupil, L. J., Adkins, S., Lacchetti, C., Schneider, B. J., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01992 · Cited by 420
GPRC5D-Targeted CAR T Cells for Myeloma
Mailankody, S., Devlin, S. M., Landa, J., Nath, K., Diamonte, C., Carstens, E. J., Russo, D., Auclair, R., Fitzgerald, L., Cadzin, B., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2209900 · Cited by 411
Bachy, E., Le Gouill, S., Di Blasi, R., Sesques, P., Manson, G., Cartron, G., Beauvais, D., Roulin, L., Gros, F. X., Rubio, M. T., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01969-y · Cited by 405
Early and late hematologic toxicity following CD19 CAR-T cells
Fried, S., Avigdor, A., Bielorai, B., Meir, A., Besser, M. J., Schachter, J., Shimoni, A., Nagler, A., Toren, A., & Jacoby, E. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0487-3 · Cited by 401
Abramson, J. S., Solomon, S. R., Arnason, J., Johnston, P. B., Glass, B., Bachanova, V., Ibrahimi, S., Mielke, S., Mutsaers, P., Hernandez-Ilizaliturri, F., et al. (2023) · Blood · doi:10.1182/blood.2022018730 · Cited by 399
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
Cappell, K. M., & Kochenderfer, J. N. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00530-z · Cited by 393
Self-citationAnti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Ramos, C. A., Grover, N. S., Beaven, A. W., Lulla, P. D., Wu, M.-F., Ivanova, A., Wang, T., Shea, T. C., Rooney, C. M., Dittus, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01342 · Cited by 386
Laetsch, T. W., Maude, S. L., Rives, S., Hiramatsu, H., Bittencourt, H., Bader, P., Baruchel, A., Boyer, M., De Moerloose, B., Qayed, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00642 · Cited by 383
Rejeski, K., Subklewe, M., Aljurf, M., Bachy, E., Balduzzi, A., Barba, P., Bruno, B., Benjamin, R., Carrabba, M. G., Chabannon, C., et al. (2023) · Blood · doi:10.1182/blood.2023020578 · Cited by 358
Jacobson, C. A., Hunter, B. D., Redd, R., Rodig, S. J., Chen, P.-H., Wright, K., Lipschitz, M., Ritz, J., Kamihara, Y., Armand, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02103 · Cited by 352
Alabanza, L., Pegues, M., Geldres, C., Shi, V., Wiltzius, J. J. W., Sievers, S. A., Yang, S., & Kochenderfer, J. N. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.013 · Cited by 351
Self-citationBase-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia
Chiesa, R., Georgiadis, C., Syed, F., Zhan, H., Etuk, A., Gkazi, S. A., Preece, R., Ottaviano, G., Braybrook, T., Chu, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2300709 · Cited by 340
Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy
Chong, E. A., Ruella, M., & Schuster, S. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2030164 · Cited by 339
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome
Hines, M. R., Knight, T. E., McNerney, K. O., Leick, M. B., Jain, T., Ahmed, S., Frigault, M. J., Hill, J. A., Jain, M. D., Johnson, W. T., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.03.006 · Cited by 338
Gauthier, J., Hirayama, A. V., Purushe, J., Hay, K. A., Lymp, J., Li, D. H., Yeung, C. C. S., Sheih, A., Pender, B. S., Hawkins, R. M., et al. (2020) · Blood · doi:10.1182/blood.2019002936 · Cited by 328
Brudno, J. N., Lam, N., Vanasse, D., Shen, Y.-W., Rose, J. J., Rossi, J., Xue, A., Bot, A., Scholler, N., Mikkilineni, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0737-3 · Cited by 311
Self-citationLong-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
Cappell, K. M., Sherry, R. M., Yang, J. C., Goff, S. L., Vanasse, D. A., McIntyre, L., Rosenberg, S. A., & Kochenderfer, J. N. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01467 · Cited by 311
Self-citationCohen, A. D., Parekh, S., Santomasso, B. D., Gállego Pérez-Larraya, J., van de Donk, N. W. C. J., Arnulf, B., Mateos, M.-V., Lendvai, N., Jackson, C. C., De Braganca, K. C., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00629-1 · Cited by 308
Mackensen, A., Haanen, J. B. A. G., Koenecke, C., Alsdorf, W., Wagner-Drouet, E., Borchmann, P., Heudobler, D., Ferstl, B., Klobuch, S., Bokemeyer, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02612-0 · Cited by 297
Hansen, D. K., Sidana, S., Peres, L. C., Colin Leitzinger, C., Shune, L., Shrewsbury, A., Gonzalez, R., Sborov, D. W., Wagner, C., Dima, D., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01365 · Cited by 293
Gardner, R. A., Ceppi, F., Rivers, J., Annesley, C., Summers, C., Taraseviciute, A., Gust, J., Leger, K. J., Tarlock, K., Cooper, T. M., et al. (2019) · Blood · doi:10.1182/blood.2019001463 · Cited by 286
Maus, M. V., Alexander, S., Bishop, M. R., Brudno, J. N., Callahan, C., Davila, M. L., Diamonte, C., Dietrich, J., Fitzgerald, J. C., Frigault, M. J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001511 · Cited by 282
Self-citationVan Oekelen, O., Aleman, A., Upadhyaya, B., Schnakenberg, S., Madduri, D., Gavane, S., Teruya-Feldstein, J., Crary, J. F., Fowkes, M. E., Stacy, C. B., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01564-7 · Cited by 279
Bhoj, V. G., Arhontoulis, D., Wertheim, G., Capobianchi, J., Callahan, C. A., Ellebrecht, C. T., Obstfeld, A. E., Lacey, S. F., Melenhorst, J. J., Nazimuddin, F., et al. (2016) · Blood · doi:10.1182/blood-2016-01-694356 · Cited by 276
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
Frey, N. V., Shaw, P. A., Hexner, E. O., Pequignot, E., Gill, S., Luger, S. M., Mangan, J. K., Loren, A. W., Perl, A. E., Maude, S. L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01892 · Cited by 271
Logue, J. M., Zucchetti, E., Bachmeier, C. A., Krivenko, G. S., Larson, V., Ninh, D., Grillo, G., Cao, B., Kim, J., Chavez, J. C., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.238634 · Cited by 271
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Ghilardi, G., Fraietta, J. A., Gerson, J. N., Van Deerlin, V. M., Morrissette, J. J. D., Caponetti, G. C., Paruzzo, L., Harris, J. C., Chong, E. A., Susanibar Adaniya, S. P., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02826-w · Cited by 270
Jain, T., Knezevic, A., Pennisi, M., Chen, Y., Ruiz, J. D., Purdon, T. J., Devlin, S. M., Smith, M., Shah, G. L., Halton, E., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002509 · Cited by 269
Mailankody, S., Matous, J. V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O. O., Malik, S., Nath, R., Anwer, F., Cruz, J. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02182-7 · Cited by 257
Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates
Taraseviciute, A., Tkachev, V., Ponce, R., Turtle, C. J., Snyder, J. M., Liggitt, H. D., Myerson, D., Gonzalez-Cuyar, L., Baldessari, A., English, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1368 · Cited by 256
Neelapu, S. S., Jacobson, C. A., Ghobadi, A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2023) · Blood · doi:10.1182/blood.2022018893 · Cited by 242
Micklethwaite, K. P., Gowrishankar, K., Gloss, B. S., Li, Z., Street, J. A., Moezzi, L., Mach, M. A., Sutrave, G., Clancy, L. E., Bishop, D. C., et al. (2021) · Blood · doi:10.1182/blood.2021010858 · Cited by 226 · cited 1×
“…cell-derived malignancies, CAR + T cell lymphoma occurred in two patients who received investigational allogeneic, donor-derived CD19-directed CAR T cells genetically modified using a PiggyBac transposon system; however, no integration of the transgene into known oncogenes was identified 151,152 .”
Strati, P., Ahmed, S., Furqan, F., Fayad, L. E., Lee, H. J., Iyer, S. P., Nair, R., Nastoupil, L. J., Parmar, S., Rodriguez, M. A., et al. (2021) · Blood · doi:10.1182/blood.2020008865 · Cited by 218
Oluwole, O. O., Bouabdallah, K., Muñoz, J., De Guibert, S., Vose, J. M., Bartlett, N. L., Lin, Y., Deol, A., McSweeney, P. A., Goy, A. H., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17527 · Cited by 218
Pennisi, M., Sanchez-Escamilla, M., Flynn, J. R., Shouval, R., Alarcon Tomas, A., Silverberg, M. L., Batlevi, C., Brentjens, R. J., Dahi, P. B., Devlin, S. M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003885 · Cited by 218
Siddiqi, T., Maloney, D. G., Kenderian, S. S., Brander, D. M., Dorritie, K., Soumerai, J., Riedell, P. A., Shah, N. N., Nath, R., Fakhri, B., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01052-8 · Cited by 207
Kadauke, S., Myers, R. M., Li, Y., Aplenc, R., Baniewicz, D., Barrett, D. M., Barz Leahy, A., Callahan, C., Dolan, J. G., Fitzgerald, J. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02477 · Cited by 205
Rejeski, K., Perez, A., Iacoboni, G., Penack, O., Bücklein, V., Jentzsch, L., Mougiakakos, D., Johnson, G., Arciola, B., Carpio, C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004475 · Cited by 202
Strati, P., Ahmed, S., Kebriaei, P., Nastoupil, L. J., Claussen, C. M., Watson, G., Horowitz, S. B., Brown, A. R. T., Do, B., Rodriguez, M. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002328 · Cited by 201
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
Levine, B. L., Pasquini, M. C., Connolly, J. E., Porter, D. L., Gustafson, M. P., Boelens, J. J., Horwitz, E. M., Grupp, S. A., Maus, M. V., Locke, F. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02767-w · Cited by 201
How I Treat Cytopenias after CAR T-cell Therapy
Jain, T., Olson, T. S., & Locke, F. L. (2023) · Blood · doi:10.1182/blood.2022017415 · Cited by 200
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells
Lichtenstein, D. A., Schischlik, F., Shao, L., Steinberg, S. M., Yates, B., Wang, H.-W., Wang, Y., Inglefield, J., Dulau-Florea, A., Ceppi, F., et al. (2021) · Blood · doi:10.1182/blood.2021011898 · Cited by 196
Locke, F. L., Neelapu, S. S., Bartlett, N. L., Lekakis, L. J., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., Timmerman, J. M., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.1547.1547 · Cited by 184
Park, J. H., Nath, K., Devlin, S. M., Sauter, C. S., Palomba, M. L., Shah, G., Dahi, P., Lin, R. J., Scordo, M., Perales, M.-A., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02404-6 · Cited by 181
Bishop, D. C., Clancy, L. E., Simms, R., Burgess, J., Mathew, G., Moezzi, L., Street, J. A., Sutrave, G., Atkins, E., McGuire, H. M., et al. (2021) · Blood · doi:10.1182/blood.2021010813 · Cited by 177 · cited 1×
“…cell-derived malignancies, CAR + T cell lymphoma occurred in two patients who received investigational allogeneic, donor-derived CD19-directed CAR T cells genetically modified using a PiggyBac transposon system; however, no integration of the transgene into known oncogenes was identified 151,152 .”
Juluri, K. R., Wu, Q. V., Voutsinas, J. M., Hou, J., Hirayama, A. V. V., Mullane, E., Miles, N., Maloney, D. G., Turtle, C. J., Bar, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004142 · Cited by 167
Zhang, M., Wei, G., Zhou, L., Zhou, J., Chen, S., Zhang, W., Wang, D., Luo, X., Cui, J., Huang, S., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00372-6 · Cited by 166
Bailey, S. R., Vatsa, S., Larson, R. C., Bouffard, A. A., Scarfò, I., Kann, M. C., Berger, T. R., Leick, M. B., Wehrli, M., Schmidts, A., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0181 · Cited by 165
Rejeski, K., Hansen, D. K., Bansal, R., Sesques, P., Ailawadhi, S., Logue, J. M., Bräunlein, E., dos Santos, D. M. C., Freeman, C. L. L., Alsina, M., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01465-x · Cited by 165
Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
Hamieh, M., Mansilla-Soto, J., Rivière, I., & Sadelain, M. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0101 · Cited by 163
Benjamin, R., Jain, N., Maus, M. V., Boissel, N., Graham, C., Jóźwik, A., Yallop, D., Konopleva, M. Y., Frigault, M. J., Teshima, T., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00245-9 · Cited by 159
CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity
Greenbaum, U., Strati, P., Saliba, R. M., Torres, J., Rondon, G., Nieto, Y., Hosing, C., Srour, S. A., Westin, J., Fayad, L. E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004575 · Cited by 158
Lu, P., Liu, Y., Yang, J., Zhang, X., Yang, X., Wang, H., Wang, L., Wang, Q., Jin, D., Li, J., et al. (2022) · Blood · doi:10.1182/blood.2021014498 · Cited by 158
Roddie, C., Dias, J., O'Reilly, M. A., Abbasian, M., Cadiñanos-Garai, A., Vispute, K., Bosshard‐Carter, L., Mitsikakou, M., Mehra, V., Roddy, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00917 · Cited by 154
Topp, M. S., van Meerten, T., Houot, R., Minnema, M. C., Bouabdallah, K. K., Lugtenburg, P. J., Thiéblemont, C., Wermke, M., Song, K., Avivi, I. M., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17673 · Cited by 147
Wehrli, M., Gallagher, K., Chen, Y., Leick, M. B., McAfee, S. L., El-Jawahri, A. R., DeFilipp, Z. M., Horick, N., O’Donnell, P. V., Spitzer, T. R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003847 · Cited by 147
Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies
Kampouri, E., Little, J. S., Rejeski, K., Manuel, O., Hammond, S. P., & Hill, J. A. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14157 · Cited by 143
Lancman, G., Parsa, K., Kotlarz, K., Avery, L., Lurie, A., Lieberman-Cribbin, A., Cho, H. J., Parekh, S. S., Richard, S., Richter, J., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0049 · Cited by 140
Gill, S. I., Vides, V., Frey, N. V., Hexner, E. O., Metzger, S. T., O'Brien, M., Hwang, W., Brogdon, J. L., Suhoski, M. M., Fraietta, J. A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007317 · Cited by 138
Alvarado, L. J., Huntsman, H. D., Cheng, H., Townsley, D. M., Winkler, T., Feng, X., Dunbar, C. E., Young, N. S., & Larochelle, A. (2019) · Blood · doi:10.1182/blood-2018-11-884486 · Cited by 134
Siddiqi, T., Soumerai, J. D., Dorritie, K. A., Stephens, D. M., Riedell, P. A., Arnason, J. E., Kipps, T. J., Gillenwater, H. H., Gong, L., Yang, L., et al. (2021) · Blood · doi:10.1182/blood.2021011895 · Cited by 127
Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma
Caimi, P. F., Pacheco Sanchez, G., Sharma, A., Otegbeye, F., Ahmed, N., Rojas, P., Patel, S., Kleinsorge Block, S., Schiavone, J., Zamborsky, K., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.745320 · Cited by 121 · cited 1×
“However, this trend was not observed with prophylactic tocilizumab on day 0, 1 h prior to infusion of T cells expressing CARs with a 4-1BB costimulatory domain in a trial involving 20 patients with LBCL, with only one patient having severe ICANS 51 (Supplementary Table 2).”
The RAIG Family Member, GPRC5D, Is Associated with Hard-Keratinized Structures
Inoue, S., Nambu, T., & Shimomura, T. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.12628.x · Cited by 114
Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells
Haas, A. R., Golden, R. J., Litzky, L. A., Engels, B., Zhao, L., Xu, F., Taraszka, J. A., Ramones, M., Granda, B. W., Chang, W., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.006 · Cited by 109
Nussenblatt, V. R., Roder, A. E., Das, S. B., de Wit, E., Youn, J.-H., Banakis, S., Mushegian, A. A., Mederos, C., Wang, W., Chung, M. C., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab622 · Cited by 106
Self-citationNeurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells
Karschnia, P., Miller, K. C., Yee, A. J., Rejeski, K., Johnson, P. C., Raje, N. S., Frigault, M. J., & Dietrich, J. (2023) · Blood · doi:10.1182/blood.2023020571 · Cited by 103
Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy
Pan, J., Deng, B., Ling, Z., Song, W., Xu, J., Duan, J., Wang, Z., Chang, A. H., Feng, X., & Tan, Y. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16176 · Cited by 99
Iacoboni, G., Rejeski, K., Villacampa, G. J., van Doesum, J. A., Chiappella, A., Bonifazi, F., López‐Corral, L., van Aalderen, M. C., Kwon, M., Martínez‐Cibrián, N., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006922 · Cited by 94
Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity
Foster, M. C., Savoldo, B., Lau, W., Rubiños, C., Grover, N. S., Armistead, P. M., Coghill, J. M., Hagan, R. S., Morrison, K., Buchanan, F. B., et al. (2021) · Blood · doi:10.1182/blood.2021010784 · Cited by 89
Kampouri, E., Walti, C. S., Gauthier, J., & Hill, J. A. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2063833 · Cited by 87
Schuster, S. J., Maziarz, R. T., Rusch, E. S., Li, J., Signorovitch, J., Romanov, V. V., Locke, F. L., & Maloney, D. G. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001304 · Cited by 81
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic
Bachanová, V., Bishop, M. R., Dahi, P. B., Dholaria, B., Grupp, S. A., Hayes‐Lattin, B., Janakiram, M., Maziarz, R. T., McGuirk, J. P., Nastoupil, L. J., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.04.008 · Cited by 81
Hill, J. A., Krantz, E. M., Hay, K. A., Dasgupta, S., Stevens‐Ayers, T., Ignacio, R. B., Bar, M., Maalouf, J., Cherian, S., Chen, X., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000717 · Cited by 78
Graham, C., Lee, W., Wiggin, H. R., Supper, V. M., Leick, M. B., Birocchi, F., Yee, A. J., Petrichenko, A., Everett, J. K., Bushman, F. D., et al. (2023) · Blood · doi:10.1182/blood.2023021429 · Cited by 78
Reynolds, G. K., Hall, V. G., & Teh, B. W. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14109 · Cited by 78
Kalaycio, M. E., Rybicki, L. A., Pohlman, B. L., Sobecks, R. M., Andresen, S. W., Kuczkowski, E., & Bolwell, B. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0673 · Cited by 76
Saini, N. Y., Swoboda, D. M., Greenbaum, U., Ma, J., Patel, R. D., Devashish, K., Das, K., Tanner, M. R., Strati, P., Nair, R., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0177 · Cited by 74
McNerney, K. O., DiNofia, A. M., Teachey, D. T., Grupp, S. A., & Maude, S. L. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0203 · Cited by 73
Miller, K. C., Johnson, P. C., Abramson, J. S., Soumerai, J. D., Yee, A. J., Branagan, A. R., O’Donnell, E., Saucier, A., Jacobson, C. A., Frigault, M. J., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00741-2 · Cited by 72
Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy
Bangayan, N. J., Wang, L., Sojo, G. B., Noguchi, M., Cheng, D., Ta, L. H., Gunn, D., Mao, Z., Liu, S., Yin, Q., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2312374120 · Cited by 71
The Black Hole: CAR T Cell Therapy in AML
Atilla, E., & Benabdellah, K. (2023) · Cancers · doi:10.3390/cancers15102713 · Cited by 68
Frigault, M. J., Nikiforow, S., Mansour, M. K., Hu, Z., Horowitz, M. M., Riches, M., Hematti, P., Turtle, C. J., Zhang, M., Perales, M., et al. (2020) · Blood · doi:10.1182/blood.2020006216 · Cited by 67
Aldoss, I. T., Khaled, S. K., Wang, X., Palmer, J. M., Wang, Y., Wagner, J. R., Clark, M. C., Simpson, J., Paul, J. A., Vyas, V., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2038 · Cited by 67
Rejeski, K., Perez, A. P., Iacoboni, G., Blumenberg, V., Bücklein, V., Völkl, S., Penack, O., Albanyan, O., Stock, S., Müller, F., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg3919 · Cited by 67
Nagle, S. J., Murphree, C. R., Raess, P. W., Schachter, L. G., Chen, A., Hayes‐Lattin, B., Nemecek, E. R., & Maziarz, R. T. (2021) · American Journal of Hematology · doi:10.1002/ajh.26113 · Cited by 66
Strati, P., Li, X., Deng, Q., Marques-Piubelli, M. L., Henderson, J. M., Watson, G., Deaton, L., Cain, T., Yang, H., Ravanmehr, V., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101158 · Cited by 66
Rejeski, K., Greco, R., Onida, F., Sánchez‐Ortega, I., Bonini, C., Sureda, A. M., Gribben, J. G., Yakoub‐Agha, I., & Subklewe, M. S. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000889 · Cited by 65
Rejeski, K., Wang, Y., Albanyan, O., Munoz, J. L., Sesques, P., Iacoboni, G., López‐Corral, L., Ries, I., Bücklein, V., Mohty, R., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27056 · Cited by 65
G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma
Galli, E., Allain, V., Blasi, R. D., Bernard, S., Vercellino, L., Morin, F., Moatti, H., Caillat‐Zucman, S., Chevret, S., & Thiéblemont, C. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01006-x · Cited by 63
Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra
Jatiani, S., Aleman, A., Madduri, D., Chari, A., Cho, H. J., Richard, S., Richter, J. R., Brody, J., Jagannath, S., & Parekh, S. S. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.04.020 · Cited by 61
Anakinra utilization in refractory pediatric CAR T-cell associated toxicities
Diorio, C. J., Vatsayan, A., Talleur, A. C., Annesley, C., Jaroscak, J., Shalabi, H., Ombrello, A. K., Hudspeth, M. P., Maude, S. L., Gardner, R. A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022006983 · Cited by 60
Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study
Gagelmann, N., Wulf, G. G., Duell, J., Glaß, B., van Heteren, P., von Tresckow, B., Fischer, M., Penack, O., Ayuk, F., Einsele, H., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008042 · Cited by 59
Gutiérrez, C., Brown, A. R., Herr, M. M., Kadri, S. S., Hill, B. T., Rajendram, P., Duggal, A., Turtle, C. J., Patel, K. B., Lin, Y., et al. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.04.008 · Cited by 57
Self-citationXue, L., Yi, Y., Xu, Q., Wang, L., Yang, X., Zhang, Y., Hua, X., Chai, X., Yang, J., Chen, Y., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00299-6 · Cited by 57
Dasatinib for treatment of CAR T-cell therapy-related complications
Baur, K., Heim, D. A., Beerlage, A., Poerings, A. S., Kopp, B., Medinger, M., Dirks, J., Passweg, J. R., & Holbro, A. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005956 · Cited by 55
Adoptive Cell Therapy for Nonhematologic Solid Tumors
Olson, D. J., & Odunsi, K. O. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01618 · Cited by 55
Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists
Drillet, G., Lhomme, F., de Guibert, S., Manson, G., & Houot, R. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008066 · Cited by 54
The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma
Chihara, D., Dores, G. M., Flowers, C. R., & Morton, L. M. (2021) · Blood · doi:10.1182/blood.2020010497 · Cited by 52
Brudno, J. N., Natrakul, D. A., Lam, N., Dulau‐Florea, A., Yuan, C. M., & Kochenderfer, J. N. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2056172 · Cited by 50
Self-citationSecond malignancies in multiple myeloma; emerging patterns and future directions
Maclachlan, K. H., Diamond, B. T., Maura, F., Hillengaß, J., Turesson, I., Landgren, O., & Kazandjian, D. G. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101144 · Cited by 49
Reagan, P. M., & Neelapu, S. S. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01616 · Cited by 49
Zurko, J. C., Johnson, B. D., Aschenbrenner, E., Fenske, T. S., Hamadani, M., Hari, P., & Shah, N. N. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0070 · Cited by 45
Brudno, J. N., Natrakul, D. A., Karrs, J. X., Patel, N., Maass‐Moreno, R., Ahlman, M. A., Mikkilineni, L., Mann, J., Stroncek, D. F., Highfill, S. L., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011470 · Cited by 41
Self-citationMarella, M., Yao, X., Carreira, V., Bustamante, M. F., Clark, H. B., Jackson, C. C., Zudaire, E., Schecter, J. M., Glover, T. D., Shenton, J. M., et al. (2022) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554221079579 · Cited by 40
Dioverti, M. V., Boghdadly, Z. E., Shahid, Z., Waghmare, A., Abidi, M. Z., Pergam, S. A., Boeckh, M., Dadwal, S., Kamboj, M., Seo, S. K., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.09.002 · Cited by 38
Mause, E. R. V., Baker, J. M., Dietze, K. A., Radhakrishnan, S. V., Iraguha, T., Omili, D. O., Davis, P. M., Chidester, S. L., Modzelewska, K., Panse, J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add7900 · Cited by 38
Kitamura, W., Asada, N., Naoi, Y., Abe, M., Fujiwara, H., Ennishi, D., Nishimori, H., Fujii, K., Fujii, N., Matsuoka, K., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18747 · Cited by 33
Lee, D. C., Jordan, A. I., Menges, M. A., Lazaryan, A., Nishihori, T., Gaballa, S. R., Shah, B. D., Pinilla-Ibarz, J. A., Baluch, A., Klinkova, O. V., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.08.011 · Cited by 31
Trab, T., Bæch, J., Jakobsen, L. H., Husby, S., Severinsen, M. T., Eloranta, S., Gørløv, J. S., Jørgensen, J. M., Gudbrandsdottir, S., Larsen, T. S., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00212-0 · Cited by 30
Wiedmeier, J. E., Iqbal, M., Rosenthal, A. C., Bezerra, E. D., García-Robledo, J. E., Bansal, R., Johnston, P. B., Hathcock, M. A., Larsen, J. T., Bergsagel, P. L., et al. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.03.002 · Cited by 27
Improved outcomes of large B‐cell lymphoma patients treated with CD19 CAR T in the UK over time
Boyle, S., Roddie, C., O'Reilly, M. A., Menne, T., Norman, J. E., Gibb, A., Lugthart, S., Chaganti, S., Arias, C. G., Jones, C. H., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.19157 · Cited by 22
Infante, M. S., Nemirovsky, D., Devlin, S. M., DeWolf, S., Tamari, R., Dahi, P. B., Lee, Y. J., Chung, D. J., Politikos, I., Barker, J. N., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.09.027 · Cited by 20
Mikkilineni, L., Natrakul, D. A., Lam, N., Manasanch, E. E., Mann, J., Weissler, K. A., Wong, N., Brudno, J. N., Goff, S. L., Yang, J. C., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2023.12.018 · Cited by 16
Self-citationJarisch, A., Wiercinska, E., Huenecke, S., Bremm, M., Cappel, C., Hauler, J., Rettinger, E., Soerensen, J., Hellstern, H., Klusmann, J., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.04.017 · Cited by 16
Zhou, L., Fu, W., Wu, S., Xu, K., Qiu, L., Xu, Y., Yan, X., Zhang, Q., Zhang, M., Wang, L., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18873 · Cited by 16
Aleissa, M. M., Little, J. S., Davey, S., Saucier, A., Zhou, G., Gonzalez-Bocco, I. H., Crombie, J. L., Looka, A., Baden, L. R., Issa, N. C., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.03.005 · Cited by 15
COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy
Kampouri, E., Hill, J. A., & Dioverti, M. V. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14144 · Cited by 15
Cornetta, K. G., Yao, J., House, K. D., Duffy, L., Adusumilli, P. S., Beyer, R. K., Booth, C., Brenner, M. K., Curran, K. J., Grilley, B., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.12.006 · Cited by 14
Self-citationWang, J., Zhang, M., Lyu, H., Guo, R., Xiao, X., Bai, X., Pu, Y., Meng, J., Li, Q., Yuan, T., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1139559 · Cited by 12
Cao, M., Han, S. R., Qiu, Y., Zhou, L., Su, Y., Tu, S., & Li, Y. (2023) · Hematological Oncology · doi:10.1002/hon.3188 · Cited by 12
Impact of corticosteroids on efficacy of BCMA targeted CAR-T therapy in multiple myeloma
Duvalyan, E., Shah, N. D., Lo, M., Martin, T. G., Wolf, J. L., Chung, A., Arora, S., Huang, C., & Wong, S. W. K. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2240920 · Cited by 11
GPRC5D-targeting chimeric antigen receptors: a new treatment for multiple myeloma?
Gagelmann, N., & Brudno, J. N. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00385-4 · Cited by 6
Self-citation
Cited by
CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review
Brudno, J. N., Maus, M. V., & Hinrichs, C. S. (2024) · JAMA · doi:10.1001/jama.2024.19462 · Cited by 359
Self-citationCao, L.-Y., Zhao, Y., Chen, Y., Ma, P., Xie, J.-C., Pan, X.-M., Zhang, X., Chen, Y.-C., Wang, Q., & Xie, L.-L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1583116 · Cited by 53
Metadata
- Authors
- Brudno, J. N., & Kochenderfer, J. N.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2024-05-20
- Volume
- 21
- Issue
- 7
- Pages
- 501-521
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W4398142342
- Cited by
- 305
- References
- 168
- FWCI
- 24.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.